Pdp (68071 3568 8)
Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 68071-3568
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 68071-3568). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
Figure 1 displays the estimated probability of achieving an initial headache response within 2 hours after treatment with rizatriptan benzoate or placebo. The plot is based on pooled data from 4 outpatient trials (Studies 1, 2, 3, and 4). The graph shows the probability of obtaining no or mild pain over time. The averages displayed are derived from patients in the trials who did not require additional treatment and achieved headache response within 2 hours.*
Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)
Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment. This plot is based on data obtained in four placebo-controlled outpatient clinical trials (Studies 1, 2, 3, and 4). The plot shows the probability of patients taking a second dose of Rizatriptan Benzoate Tablets or other medication for migraines over time. The data includes patients who had a headache response at 2 hours and those who had no response to the initial dose. Remedication was not allowed within 2 hours post-dose.*
Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
Not available.*
Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose O (Rizatriptan Fig4)
Figure 4 shows the estimated probability of patients taking a second dose of Rizatriptan Benzoate Orally Disintegrating Tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled Studies 5 and 6. The graph represents the percentage of patients taking a second dose or rescue medication at different time points post dose. The data used to create the graph is obtained from two placebo-controlled outpatient clinical trials, and patients who did not use additional treatments were censored at 24 hours. The plot includes both patients who had a headache response at 2 hours and those who did not respond to the initial dose.*
Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
This text appears to be a figure or graph displaying the observed percentage of patients reporting no headache pain by 2 hours after taking a dose in Study 7. It seems to be comparing the effectiveness of Rizatriptan Benzoate OD Tablets versus a placebo. The graph shows percentages from 0% to 100% in increments of 10% and includes data points at various percentages. The x-axis represents the number of hours post stage 2 dose, with intervals marked at 10, 15, and 20 hours. Overall, this graph provides information on the pain relief response rate of Rizatriptan Benzoate OD Tablets compared to the placebo in Study 7.*
Chemical Structure (Rizatriptan Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
